N@N

ConjuChem announces management change

_{//health-fitness.news-articles.net/content/2009/05/15/conjuchem-announces-management-change.html}
^{Published in Health and Fitness on Friday, May 15th 2009 at 14:08 GMT, Last Modified on 2009-11-02 12:16:59 by Market Wire}  

 MONTREAL, May 15 /CNW/ - ConjuChem Biotechnologies, Inc. (TSX:CJB) announced today that Lennie Ryer, Vice President and Chief Financial Officer, will be leaving the Company effective May 15. "I would like to thank Lennie for his many years of service and contribution to ConjuChem," commented Mark Perrin, President and CEO. Additionally, the Company announced the promotion of Chantal Lapointe, CA to the role of Vice President, Finance. Previously, Mrs. Lapointe was Director, Finance and Administration at ConjuChem. She has been with the Company since 1998, prior to the Company's IPO, and has been directly involved with all the Company's financial operations for the last eleven years. Mrs. Lapointe is a graduate of the Université du Québec à Montréal and holds a Bachelor degree in accounting. Regarding the appointment, Mark Perrin stated, "I am very pleased to recognize Chantal's accomplishments and look forward to her future contributions to the Company." About ConjuChem ConjuChem, developer of next generation medicines from therapeutic peptides, is creating long-acting compounds based on bioconjugation platform technologies. When applied to peptides, the Company's systemic PC-DAC(TM) Technologies enable the creation of new drugs with significantly enhanced therapeutic properties as compared to the original peptide. The Company has two major development programs: PC-DAC(TM):Exendin-4, a GLP-1 agonist in Phase II and PC-Insulin, a long-acting basal insulin in preclinical testing. Detailed descriptions of the Company and its technologies can be viewed on the Company's website [ www.conjuchem.com ]. Forward-Looking Statements Some of the statements made herein may constitute forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause ConjuChem's actual results, performance or achievements to be materially different from those expressed or implied by any of the Company's statements. Actual events or results may differ materially. We disclaim any intention, and assume no obligation, to update these forward-looking statements. 

For further information: Mark Perrin, President and CEO, ConjuChem Biotechnologies Inc., (514) 844-5558 ext 311, [ perrin@conjuchem.com ]; James Smith, Investor Relations, (416) 815-0700 ext. 229, [ JSmith@equicomgroup.com ]